SML1227
Tavaborole
≥95% (HPLC), protein synthesis inhibitor, powder
Synonym(s):
1,3-Dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, AN-2690, AN2690
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C7H6BFO2
CAS Number:
Molecular Weight:
151.93
UNSPSC Code:
12352200
NACRES:
NA.77
Product Name
Tavaborole, ≥95% (HPLC)
SMILES string
B1(OCc2c1ccc(c2)F)O
InChI
1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
InChI key
LFQDNHWZDQTITF-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
Quality Level
Related Categories
General description
Tavaborole is a boron-based pharmaceutical agent. It has broad-spectrum oxaborole antifungal activity. Due to its low molecular weight, it facilitates maximal nail plate penetration than its predecessors.
Biochem/physiol Actions
Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS).
Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS). Tavaborole forms a covalent adduct with the 3′ adenosine of tRNA(leu) at the editing site of fungal, but not bacterial LeuRS, locking the enzyme in an inactive conformation. Tavaborole was recently approved for the treatment of onychomycosis of the toenail in adults.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Spotlight on tavaborole for the treatment of onychomycosis
Jinna S and Finch J
Drug design, development and therapy, 9, 6185-6185 (2015)
Tavaborole for the treatment of onychomycosis
Elewski BE and Tosti A
Expert Opinion on Pharmacotherapy, 15(10), 1439-1448 (2014)
The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
Toledo-Bahena ME, et al.
J. Drugs Dermatol., 13(9), 1124-1132 (2014)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service